NCT06969573View on ClinicalTrials.gov

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
DRUG

Placebo

Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 36 mcg

Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 78 mcg

Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

Trial Locations (1)

T6G2R3

RECRUITING

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER